Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Rhea-AI Summary
Virax Biolabs (NASDAQ: VRAX) approved a 1-for-25 share consolidation, effective June 26, 2026. Shares will trade on a post-consolidation basis under symbol VRAX with new CUSIP G9495L133.
The move aims to regain compliance with Nasdaq Rule 5550(a)(2) on the $1.00 minimum bid price.
Positive
- 1-for-25 share consolidation to help regain compliance with Nasdaq Rule 5550(a)(2)
- Post-consolidation trading on Nasdaq Capital Market continues under symbol VRAX
- No change to each shareholder’s percentage ownership, aside from fractional share rounding
- Fractional shares rounded up to the next whole share, avoiding loss of value
Negative
- None.
News Market Reaction – VRAX
In the Jun 24 session, VRAX declined 14.78%, reflecting a significant negative market reaction. Argus tracked a trough of -30.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Clinical data update | Positive | -18.2% | Reported positive early pilot data for ViraxImmune in Long COVID and PAIS. |
| Apr 14 | Strategy update | Positive | -11.1% | CEO letter outlining strategy, milestones and cash position versus market cap. |
| Mar 31 | ISO certifications | Positive | +35.3% | Announced ISO 13485 and ISO 9001 certifications for quality management system. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
VRAX has often traded lower following otherwise positive corporate or clinical updates, with only occasional strong positive reactions.
Key Terms
nasdaq marketplace rule 5550(a)(2) regulatory
cusip financial
memorandum and articles of association regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
At the opening of trading on June 26, 2026, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L133. The objective of the Share Consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least
Upon the effectiveness of the Share Consolidation, every twenty-five issued and outstanding ordinary shares of a par value of US
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is developing T cell-based test technologies intended to support an immunology profiling platform. T cell testing may have applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.
In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of preliminary, interim or top-line data to accurately reflect the complete results of a trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA and other regulators' agreement on the regulatory path for ViraxImmune™ or other potential products; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.
These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.
View original content:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-302808727.html
SOURCE Virax BioLabs Group Limited